Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05512962 · ClinicalTrials.gov registry record · Phase 2
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
A Phase 2 study of Diabetic Macular Edema, sponsored by Oxular Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 6
- Study locations
NCT05512962 is a Phase 2 study of Diabetic Macular Edema that has completed, run by Oxular Limited. The registered enrollment target is 25 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT05512962, a Phase 2 study of Diabetic Macular Edema, has completed, sponsored by Oxular Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with Diabetic Macular Edema.
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide
- DEVICE Semi-automated Suprachoroidal Microcatheter
Study Locations (6)
Texas
- Austin Retina Associates - Austin
- Retina Consultants of Texas - The Woodlands - Houston
- Retina Consultants of Texas - Bellaire - Houston
- Retina Consultants of Texas - San Antonio - San Antonio
California
- California Retina Consultants - Bakersfield
Minnesota
- Retina Consultants of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05512962
The ClinicalTrials.gov registry entry for NCT05512962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Oxular Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT05512962 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Texas, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05512962 about?
NCT05512962 is a clinical study titled "Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema". The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with Diabetic Macular Edema.
What is the current status of trial NCT05512962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-08-31. Estimated completion is 2023-11-30.
What conditions does trial NCT05512962 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT05512962?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Semi-automated Suprachoroidal Microcatheter (DEVICE).
Who is sponsoring clinical trial NCT05512962?
This trial is sponsored by Oxular Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05512962 being conducted?
This trial has 6 study locations across California, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.